Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2016-07-13 10:14:42)
Á¦¸ñ [³í¹®] [2013]Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase In
³»¿ë

Korean J Pathol. 2013 Feb;47(1):52-60. doi: 10.4132/KoreanJPathol.2013.47.1.52. Epub 2013 Feb 25.

Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment.

Lee HJ1Xu XKim HJin YSun PKim JEChung JH.

Author information

Abstract

BACKGROUND:

The aims of this study were to evaluate the abilities of direct sequencing (DS), peptide nucleic acid (PNA) clamping, and pyrosequencing methods to detect epidermal growth factor receptor (EGFR) mutations in formalin-fixed paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) samples and to correlate EGFR mutational status as determined by each method with the clinical response to EGFR tyrosine kinase inhibitors (TKIs).

METHODS:

Sixty-one NSCLC patients treated with EGFR TKIs were identified to investigate somatic mutations in the EGFR gene (exons 18-21).

RESULTS:

Mutations in the EGFR gene were detected in 38 of the 61 patients (62%) by DS, 35 (57%) by PNA clamping and 37 (61%) by pyrosequencing. A total of 44 mutations (72%) were found by at least one of the three methods, and the concordances among the results were relatively high (82-85%; kappa coefficient, 0.713 to 0.736). There were 15 discordant cases (25%) among the three different methods.

CONCLUSIONS:

All three EGFR mutation tests had good concordance rates (over 82%) for FFPE samples. These results suggest that if the DNA quality and enrichment of tumor cells are assured, then DS, PNA clamping, and pyrosequencing are appropriate methods for the detection of EGFR mutations.



 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 28873
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29210
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6067
   45           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 20973
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8123
   43           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1175
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5816
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6097
¢º           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25286
   39           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14321
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22242
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3387
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14157
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1166
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4027
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8822
   32           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14477
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1171
   30           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 3893
 

< 1 2 3 >